HERON ELAINE J

PVLA Director Heron purchases 2,400 shares at $125.00 for $300,000.00

Director Elaine J Heron purchased 2,400 shares at $125.00 on 2026-02-27, expanding her holdings from 45,412 to 47,812 shares (a +5.3% increase). The transaction occurred when the stock was trading 10.6% below its 52-week high of $148.34, following a 72.9% surge over the preceding 30 days. However, this purchase should be contextualized against Heron's cross-ticker insider trading track record: across all her open-market transactions, her prior 2 buys averaged -9.1% returns at both 30 and 90 days, with a 0.00% win rate. Palvella itself remains unprofitable with a full-year net income of -$11,345,000.00 and zero quarterly revenue, though the company has demonstrated +65.3% annual revenue growth. The timing and modest 5.3% increase in holdings, combined with the insider's historically poor buy timing across other securities, suggests this transaction warrants observation rather than confidence signaling.

Director Heron purchases 40,000 shares of VXRT at blended $0.40 avg, raising stake 70.7% to 96.6K shares

Director Elaine J Heron purchased 40,000 shares across 2 transactions on 2025-11-17 at a blended average price of $0.40 per share, materially expanding her position from 56,566 shares to 96.6K shares. The stock currently trades at $0.36, down 61.7% from its 52-week high of $0.94, placing this purchase at a depressed valuation relative to recent trading range. Vaxart remains unprofitable (full-year net income was negative) despite exceptional revenue growth of +288.9% year-over-year, creating a paradoxical fundamental picture that complicates interpretation of the director's motivation. The absence of prior track record data for this insider prevents assessment of historical execution accuracy at this ticker.